Crossbeta Biosciences completes financing round and appoints Guus Scheefhals as CEO
Crossbeta Biosciences announced that it has successfully completed a financing round of up to Eur 2 million, which is funded by new as well as existing shareholders and also includes an Innovation Grant from SenterNovem. The financing will be used to further advance Crossbeta’s technology in several therapeutic areas and to establish a stronger position for co-development programs and commercialization partnerships.
At the same time, Crossbeta Biosciences announced the appointment of Guus Scheefhals as Chief Executive Officer. Guus Scheefhals previously worked at Avantium in several managerial positions, most recently as Chief Operating Officer of the business unit Pharma. Before Avantium Guus Scheefhals held commercial positions at DSM Biologics, Analytico, and NPBI, which is now part of Fresenius. Guus Scheefhals holds a Masters Degree in Pharmacy from the Utrecht University.
With the appointment of Guus Scheefhals, Johan Renes steps down as CEO after being with the company from the start and since 2 years as part-time CEO.
Other news from the department people
